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ABSTRACT
Metastatic disease is the leading cause of pancreatic ductal adenocarcinoma (PDAC) associated death. PDAC cells 
invade and enter the bloodstream early, before frank malignancy can be detected. Our objective was to develop an in 
vivo assay enabling the identification and quantification of circulating tumor cells (CTCs) from primary orthotopic PDAC 
tumors. Human PDAC cells expressing luciferase and green fluorescent protein were orthotopically injected into the 
pancreas of mice utilizing ultrasound guidance. Bioluminescent imaging was conducted to identify and track tumor 
growth. CTCs were then isolated and analyzed by flow cytometry to detect GFP-expressing cancer cells. Tumor growth 
as measured by bioluminescent imaging increased over time. The concentration of CTCs correlated with the strength 
of bioluminescent imaging signal. In addition, livers bearing macroscopic disease were harvested for further imaging 
under fluorescence stereomicroscopy and confocal microscopy, which confirmed the presence of metastases. This 
study represents an orthotopic animal model that reliably detects the presence of CTCs from PDAC. There is a positive 
correlation between the concentrations of CTCs with overall tumor burden.
Keywords: pancreatic adenocarcinoma, circulating tumor cells, metastasis, bioluminescent imaging, orthotopic im-
plantation
INTRODUCTION
Pancreatic adenocarcinoma (PDAC) is the 3rd leading cause of cancer 
related deaths in the United States in spite of accounting for only 3.2% 
of new cancer cases [1]. The lethal nature of this disease can partly be 
explained by its early proclivity for progression. At diagnosis, 52% of 
patients already have metastatic disease and an additional 29% have 
regional lymph node spread, portending very poor 5-year survival rates 
of 2.7% and 11.5%, respectively [1]. Even patients diagnosed early with 
stage I disease have 5-year survival rates of only 30%, due to the fact 
that the majority of patients undergoing surgical resection have either 
local or distant disease recurrence at a median of 16.2 months following 
surgery [2-4]. Of individuals who do have disease recurrence, nearly 80% 
have metastases [3]. The reason for this phenomenon can be attributed to 
the early metastatic progression of the disease, which can occur before 
primary tumor is detectable [5]. Some have even proposed the possibility 
of metastases developing prior to pathologically observable basement 
membrane invasion and in parallel with primary tumor development 
[5]. Suffice it to say, PDAC may be a systemic disease and treatment 
strategies must evolve to better target the systemic disease features.
Circulating tumor cells (CTCs) represent a potential treatment target 
for systemic disease control. CTCs are tumor cells that detach from pri-
mary tumors and enter the circulation with the potential to seed distant 
tissues and form metastatic disease foci. The concept of CTCs was first 
described in 1869 [6], but only in the past few decades have technological 
advances begun to facilitate their detection and characterization. Since 
then, interest in CTCs has grown tremendously. CTCs have been dis-
covered to have prognostic value and the potential to serve a minimally 
invasive, real-time “liquid biopsy” method to enhance clinical decision 
making without the need to expose patients to the risks of potentially 
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dangerous procedures to collect tissue in already frail patients [7,8].
CTCs may originate from primary tumors via passive shedding or 
active migration into blood vessels [9]. In mouse models of pancreatic 
cancer, active cancer cell intravasation may be facilitated by epitheli-
al-to-mesenchymal transition (EMT) of the cancer cells, which produced 
a more invasive cellular phenotype [5]. However, using lineage tracing 
techniques in similar mouse models of pancreatic cancer, it has been 
demonstrated that cells producing metastatic colonies at distant sites do 
not necessarily have to undergo EMT [10]. Regardless of their origin, 
very few CTCs manage to give rise to productive metastatic colonies. 
This is the likely result of various extrinsic factors that reduce the survival 
of CTCs during their passage through the circulatory system as well 
as the intrinsic capacity of individual CTCs to survive and grow in a 
metastatic end organ such as the liver [11,12]. However, it is reasonable 
to believe that the number of CTCs is an important factor to consider 
when it comes to assessing metastatic potential.
Clinically, CTC number has been well known to correlate with overall 
prognosis in patients with breast, lung, prostate and colorectal cancers 
[13-16]. More recently, similar correlations have been discovered for 
pancreatic cancer [17-19]. CTCs have been found in all stages of PDAC 
but higher CTC numbers are known to correlate with metastatic disease 
and predict shorter median progression free survival and overall survival 
[17,18,20-22]. Thus, treatments that produce significant decreases in 
CTCs may translate to a reduction in metastatic disease potential, and 
thus improve overall survival. Reproducible and reliable animal mod-
els would be invaluable tools to carry out these investigations. In the 
current study, we demonstrate a novel animal model employing tumor 
cells modified to facilitate simple identification and quantification in 
the circulation. Such a model has the potential to design experiments 
exploring treatments on metastatic behavior of PDAC.
MATERIALS AND METHODS
Cell culture
The human PDAC cell line, MIA PaCa-2, was obtained from Amer-
ican Type Culture Collection and passaged routinely for less than 6 
months from the time of receiving them. Cells were grown in DMEM 
high glucose media supplemented with 10% fetal bovine serum and 1% 
penicillin/streptomycin. Luciferase and GFP expressing MIA PaCa-2 
cells were generated using pQClucIN and pMSCV-IRES-GFP plasmids 
as previously described [23].
Calibration curve
Luciferase and GFP expressing MIA PaCa-2 cells were added to 
whole blood in known concentrations (20000 cells/ml, 10000 cells/ml, 
5000 cells/ml, 1000 cells/ml, 500 cells/ml, 25 cells/ml and 0 cells/ml). 
Blood samples underwent immediate red blood cell lysis by addition 
of ~10 ml of lysis buffer followed by centrifugation at 300 G for 5 
min. The resulting supernatant was aspirated and the procedure was 
repeated. Samples were resuspended in FACS buffer that contained 1 
× 105 polystyrene FluoSpheres (Molecular Probes, Eugene OR) per ml. 
CTCs in each sample were detected and quantified using flow cytometry 
and a known concentration of microspheres as stated above. FACS 
buffer containing microspheres that are fluorescent in the scarlet region 
(645/680) were used to set gates for spheres in forward and side scatter. 
A sample of blood alone was used to determine where lymphocytes fall 
in forward and side scatter. A control sample of blood containing a known 
concentration of tumor cells (1 × 106) was used to identify the popula-
tion of GFP expressing cells in forward and side scatter. Gates were set 
for single cells, Hoeschst negative cells and signal intensity. Samples 
were run on a LSR II (BD Biosciences, λex = 645 nm and λem = 680 nm) 
flow cytometer and analysis performed utilizing FlowJOTM software. 
Results were used to determine circulating tumor cell concentration 
(CTC/ml) for each sample by the equation [number of CTCs detected/
(FluoSpheres detected/100000 FluoSpheres/ml)]. This was correlated 
to final tumor volume obtained from bioluminescent imaging. The 
concentration of cells detected correlated with its known concentration 
by Pearson’s linear regression.
Orthotopic intrapancreatic injection and biolumines-
cent image analysis
Female six week old athymic-nu/nu mice were purchased from Envigo 
and handled in accordance with the University of Iowa Animal Care 
and Use Committee (IACUC). MIA PaCa-2 cells (4 × 105) expressing 
luciferase and GFP were injected orthotopically directly into the pan-
creas of mice using ultrasound guidance as previously described [24]. 
Cells were suspended in a 1:1 mixture of PBS and Matrigel (Corning, 
St. Louis, MO) immediately prior to injections to prevent cells from 
dispersing throughout the abdomen. Tumor formation and growth were 
monitored weekly through bioluminescent imaging. Mice were given 
IP injections (200 µl) of a 15 mg/ml solution of VivoGloTM luciferin 
(Promega, Madison, WI). Following injection, mice were anesthetized 
by isoflurane inhalation and imaged using the AMI-1000 (Spectral 
Instruments Imaging). Total photon flux (photons per second) was 
quantified (AMIView software) by placing and area of interest around 
each mouse. Tumor progression was allowed to continue for fifty days 
post cancer cell injection.
CTC isolation and analysis
CTCs were isolated from mice following ultrasound guided orthot-
opic injection. Mice were anesthetized and injected with luciferin prior 
to cardiac blood draws. Cardiac blood draws were performed using 
heparinized needles and syringes to obtain roughly 1 ml of circulatory 
volume. Blood samples underwent immediate red blood cell lysis as 
described above for the calibration curve experiment. Spearman’s rank 
correlation was used to assess for significance at the ≤ 0.05 level using 
GraphPad Prism 7.0 (San Diego, CA).
Ex vivo imaging
Following cardiac draw, the mouse pancreas and liver were removed 
and ex vivo imaging was performed to confirm the presence of a primary 
pancreatic tumor and identify any hepatic metastatic disease. Organs 
were kept in the dark and on ice in cold PBS or HBSS prior to and 
during imaging. Bioluminescence was used to identify the presence 
of luciferase expression as previously described above. Fluorescent 
imaging of whole organs for the identification of GFP was performed 
on an Olympus Fluorescent Stereoscope. Cytoplasmic GFP immuno-
fluorescent staining of pancreas and liver samples fixed in OCT were 
viewed under 63× magnification. Sections (10 µm) were cut using a 
MICROM HM 505E, mounted in VectaShield Mounting Medium with 
DAPI (Vector Laboratories, Burlingame, CA) and viewed with a Zeiss 
710 Laser Scanning Confocal Microscope (1 S10 RR025439-01).
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Hepatic tumor cell isolation
Liver specimens with visible metastatic lesions were used to isolate 
tumor cells to test for the presence of GFP and luciferase expression. 
Hepatic sections were quickly minced with a scalpel in 5 ml of cold 
HBSS (with Ca2+ and Mg2+) on ice. Tissue fragments and buffer were 
transferred to a conical tube and centrifuged at 450 RCF for 2 min at 
4°C. The supernatant was aspirated and 5 ml of 0.5% w/v collagenase 
made up in HBSS containing Ca2+ and Mg2+ was added followed by 
incubation for 5 min at 37°C. After incubation, fragments were resus-
pended 5–10 times followed by further incubation at 37°C for a total 
of 30 min. Each resuspension utilized progressively decreasing pipette 
sizes (25 ml–2 ml). An equal volume of cold HBSS without Ca2+ and 
Mg2+ was added followed by centrifugation at 450 RCF for 2 min at 
4°C. The supernatant was aspirated and the cell pellet was washed 2 
times followed by centrifugation prior to being resuspended as single 
cells in DMEM high glucose media containing 10% FBS, 1% penicillin/
streptomycin and 1% non-essential amino acids. Cells were plated in 
a T25 tissue culture filter top flask and allowed to attach before being 
examined for GFP expression.
RESULTS
Calibration curve
A calibration curve of MIA PaCa-2 cells expressing GFP and lucif-
erase was generated following the addition of known concentrations of 
cells (range 25–20000 cells/ml) to whole blood and subsequent RBC 
lysis (Fig. 1). Our regression analysis indicates 66% of cells are detected 
from known concentrations. The correlation of the regression model 
is significant across the entire range of concentrations tested showing 
an r2 value of 0.99.
Orthotopic intrapancreatic injection and biolumines-
cent image analysis
Ultrasound guided injections were performed directly into the pan-
creas medial and inferior to the spleen. This “V”-shaped pocket between 
the kidney and spleen was visualized by ultrasound as demonstrated 
in Figure 2A. Tumor cells were injected into the lower apex of this 
region and can be directly visualized following injection as a region 
of hyperechogenicity as indicated by the arrow (Fig. 2A). Weekly 
bioluminescent expression was quantified for each mouse and tracked 
over time. A representative color scaled image indicating photons/s 
superimposed over a photograph from mice on days 13 and 49 are 
shown in Figure 2B. Progression of the average tumor growth curve 
for each of the five mice injected with tumor is shown in Figure 2C. 
Four out of five mice injected with PDAC showed progressive increases 
in photon flux compared to background throughout the duration of the 
experiment. The combined tumor growth increased over time with the 
final average being 1.1 × 109 ± 0.7 × 109 photons/s (Fig. 2C).
Confirmation of GFP expression
Orthotopic primary pancreatic tumors were confirmed by ex vivo 
GFP microscopy in the explanted whole pancreas (representative image, 
Fig. 3A). In addition, two mice (# 1 & 5) were found to have small foci 
of metastatic disease in the liver as confirmed by ex vivo GFP micros-
copy (representative image, Fig. 3B). GFP immunofluorescence was 
also confirmed in the cell cytoplasm of primary pancreatic tumor and 
liver metastases fixed in OCT, sectioned and imaged under magnifi-
cation (representative images, Fig. 3C and 3D). Single cell isolation 
from hepatic tumor metastases was performed and confirmed by GFP 
microscopy (representative image, Fig. 3E and 3F).
Figure 1. MIA PaCa-2-Luc-GFP calibration curve. Luciferase and GFP expressing MIA PaCa-2 cells were added to whole blood in known concen-
trations. RBC lysis procedures were carried out and samples were analyzed by flow cytometry for tumor cell quantification. The concentration of cells 
detected correlated with its known concentration by a Pearson’s linear regression (y = 0.66x, r2 = 0.99, Mean ± SEM).
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Figure 2. Methods for developing orthotopic circulating tumor cell 
model. A. MIA PaCa-2 pancreatic adenocarcinoma cells (4 × 105) sus-
pended in a 1:1 mixture of PBS and Matrigel were injected into athymic 
nude mice sedated with isoflurane. Ultrasound guided injections were 
performed directly into the pancreas medial and inferior to the spleen. 
The spleen, pancreas, and kidney are labeled. The arrow represents a 
consolidation of injected cells suspended in Matrigel within the pancreas. 
B. Tumor volumes were measured weekly via bioluminescent imaging on 
an AMI-1000 imager. Mice were imaged 5 min after intraperitoneal injection 
of 15 mg/ml luciferin. Representative bioluminescent images are shown 
for days 13 and 50 which display an increase of bioluminescence over 
time. C. Log of photon flux (photons/s) for each mouse and a combined 
average is shown over the 49 d period following tumor cell injection. Mice 
displayed a progressive increase of photon flux over time. Tumor growth 
over time increased by an average of 1.1 × 109 ± 0.7 × 109 photons/s. A 
region of interest was placed around each mouse and total photon flux 
was quantified utilizing the AMIView software. Data reported as means ± 
SEM of total photon flux (photons per second).
Figure 3. Ex vivo pancreatic and liver GFP fluorescent imaging for 
primary and metastatic tumor identification. A. Immediately following 
cardiac draw and mouse sacrifice, the pancreas and liver were removed 
for ex vivo imaging under an Olympus Fluorescent Stereoscope to confirm 
primary pancreatic tumor from GFP expressing MIA PaCa-2 cells. B. Liver 
metastasis from GFP expressing MIA PaCa-2 cells. Arrow corresponds to 
liver metastasis. C. GFP immunofluorescent staining of primary pancreatic 
tumor. D. GFP immunofluorescent staining of liver metastasis. Specimens 
were fixed in OCT for immunofluorescent staining, cut into 10 µm section 
using a MICROM HM 505E, mounted in VectaShield Mounting Medium with 
DAPI and viewed with a Zeiss 710 Laser Scanning Confocal Microscope. 
Green areas represent positive GFP staining within the cell cytoplasm in 
both pancreatic and liver specimens. Blue areas represent cell nuclei. E. 
Bright field. F. GFP expression. Liver specimens with visible metastatic 
lesions were used to isolate single tumor cells to test for the presence of 
GFP expression. Hepatic sections were quickly minced with a scalpel in 
cold HBSS and centrifuged before the addition of 0.5% w/v collagenase. 
Cells were plated and allowed to attach before being examined for GFP 
expression at 20× magnification.
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Circulating tumor cell identification and quantification
Serum samples processed through RBC lysis were evaluated by 
flow cytometry and sorted for GFP expression to indicate tumor cells 
shed into circulation (Fig. 4A). A known concentration of microspheres 
allowed the exact volume passing through the flow cytometer to be 
determined and facilitated an accurate quantification of CTCs con-
centration. All of the mice injected with PDACs displayed detectable 
levels of CTCs with GFP expression and were compared to a known 
control for quantification. A histogram indicating the total number of 
CTCs detected by flow cytometry for each mouse is shown in Figure 
4B. CTCs concentration ranged from 21 CTCs/ml to 7791 CTCs/ml 
(Fig. 5A) with a mean concentration of CTCs of 3092. The concen-
tration of CTCs for each mouse was then plotted against overall final 
tumor burden and a linear regression model was produced (Fig. 5B) 
demonstrating a positive correlation (r2 = 1.0; P < 0.05).
Figure 4. Flow cytometry detection of circulating tumor cells. A. Lysed 
preparation of red blood cells made up in FACS buffer containing polystyrene 
FluoSpheres was used for quantification. Samples demonstrate gating of 
microspheres, which are shown in blue, while gating of GFP expressing 
circulating tumor cells are shown in green, and all other cells which are 
present but not quantified, are shown in red. B. Histogram indicating the 
total number of CTCs detected in circulation for each mouse.
Figure 5. Determination of circulating tumor cell concentration. A. 
CTC concentration (CTCs/ml) was determined for each mouse. Mouse #4 
contained the lowest concentration (21 CTCs/ml) and mouse #1 contained 
the highest concentration (7791 CTCs/ml). B. Serum CTC concentration 
was plotted against overall final tumor burden and a Spearman’s rank 
correlation for linear regression confirmed correlation and was found to 
be significant (r2 = 1.0; P < 0.05).
DISCUSSION
Cancer treatment in general has improved immensely over the last 
quarter century; however, treatment breakthroughs for PDAC have 
been elusive. PDAC is highly aggressive and often metastasizes well 
before symptoms develop precluding surgical options for cure [1]. Even 
localized disease commonly recurs in distant sites following surgical 
resection and adjuvant chemotherapy [25], perhaps indicating both the 
high frequency of undetectable metastatic disease in these patients and 
the high level of resistance this disease has to current systemic che-
motherapies. Thus, PDAC is a highly aggressive systemic disease, but 
the systemic dimension is poorly understood. A principle challenge in 
accumulating reliable systemic disease data has been a lack of reliable 
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methodology to measure systemic disease and metastatic potential. 
Circulating tumor cells are widely thought to be the link between pri-
mary tumor and metastatic disease [26]. The purpose of this study was 
to develop a method for detecting and quantifying circulating tumor 
cells in mice inoculated with primary human PDAC as a tool to study 
the systemic dimension of this aggressive disease.
Our results show that PDACs from whole blood can be reliably 
detected by flow cytometry and may be quantified over a wide range 
of concentrations making it possible to measure levels of circulating 
tumor cells in vivo. The present study provides a novel animal model 
to detect and quantify PDAC CTCs in orthotopic xenografts. Over the 
seven week study period, pancreatic tumors grew appreciably. The 
correct anatomic placement of the tumor is critical to the design of 
the model and has two key considerations. First, orthotopic placement 
enables primary tumor cells to enter the hepatic circulation as they 
would in human subjects via the portal system, as opposed to the sys-
temic circulation which is the route of entry for heterotopic xenograft 
models. This theoretically preserves the metastatic circulatory pathway 
under study and provides a high fidelity method to study tumor cells 
entering circulation. Indeed, foci of metastatic disease were discovered 
in the examined liver tissue and confirmed by GFP expression under 
stereomicroscopy and ex vivo bioluminescent imaging. Secondly, CTCs 
collected by cardiac draw from orthotopic tumors are filtered through 
the liver when compared to flank tumors and may reduce the number of 
detectable CTCs. However, when applied consistently, this method can 
be used as an objective way to measure how various treatments affect 
the circulating tumor volume and whether those treatments translate 
to alterations in metastatic potential.
Interestingly, this data also demonstrated a correlation between the 
concentration of CTCs and the size of the solid tumor burden, as indi-
cated by bioluminescent signal strength. This may suggest that larger 
PDAC tumors are likely to shed more metastatic cells into circulation 
where there is opportunity to seed distant tissues as metastatic disease 
foci. This finding is consistent with correlations already known to be 
true that larger cancers are more likely to spread [27].
There are certain limitations to this study. Notably, it is impossible 
to distinguish primary tumors from metastatic lesions with abdominal 
bioluminescent images alone due to light scatter and refraction within 
the abdomen. However, the bioluminescent intensity does provide 
a good measure for total solid tumor burden. In our experience, the 
most reliable way to determine the presence of metastatic disease is 
by post mortem pathologic examination in combination with ex vivo 
bioluminescent imaging. Additionally, confirmation of primary tumor 
in the pancreatic parenchyma is limited to evidence supplied by imme-
diate visualization on ultrasound imaging and post mortem pathologic 
examination demonstrating tumor in the pancreas.
Circulating tumor cell detection is not currently part of the standard 
clinical workup for patients with suspected or confirmed pancreatic 
cancer. However, there have been recent improvements in the accuracy 
of human PDAC CTC detection methods. As a diagnostic tool, one study 
has reported a CTC detection sensitivity and specificity of 75% and 
96%, respectively with an area under the receiver operating characteristic 
curve (AUROC) of 0.867 [18]. There is significant prognostic value as 
well. Higher CTC numbers (< 3 CTCs/ml) have been shown to trend 
toward lower median overall survival (11.5 months vs. 20 months) [17] 
and cell surface phenotype expression (epithelial vs. mesenchymal) also 
appears to predict disease recurrence and survival [19]. Considering the 
progress thus far, it is conceivable that CTC detection and enumeration 
may assist with diagnosis, staging, prognostication, and treatment 
response monitoring for patients with PDAC.
In summary, our analysis describes a dependable animal model for 
studying PDAC metastases. Genetically modified orthotopic PDAC 
tumor xenografts can produce detectable CTCs and the concentration 
is dependent on the amount of tumor burden. This is the first study 
detecting CTCs in mice utilizing human orthotopic PDAC xenografts 
which carries significant potential for future study as a reliable tool to 
identify treatments with a high capacity for decreasing the number of 
tumor cells in circulation and potentially generating patient survival 
advantages.
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